Non-invasive STEMI-related biomarkers based on meta-analysis and gene prioritization

Background and aims: Acute ST-Segment Myocardial infarction (STEMI) is a common cardiovascular issue with a considerable burden of the disease. The underlying genetic basis and non-invasive markers were not well-established. Methods: Here, we implemented a systematic literature review and meta-analyses integration methods on 217 STEMI patients and 72 normal individuals to prioritize and detect the STEMI-related non-invasive markers. Five high-scored genes were experimentally assessed on 10 STEMI patients and 9 healthy controls. Finally, the presence of co-expressed nodes of top-score genes was explored. Results: The differential expression of ARGL, CLEC4E, and EIF3D were significant for Iranian patients. The ROC curve for gene CLEC4E revealed an AUC (95% CI) of 0.786 (0.686-0.886) in the prediction of STEMI. The Cox-PH model was fitted to stratify high/low risk heart failure progression (CI-index = 0.83, Likelihood-Ratio-Test = 3e-10). The SI00AI2 was a common biomarker between STEMI and NSTEMI patients. Conclusions: In conclusion, the high-scored genes and prognostic model could be applicable for Iranian patients.

Automated summary

This study identified the STEMI-related non-invasive markers and found that ARGL, CLEC4E, and EIF3D genes showed significant differential expression in Iranian patients. The ROC curve for CLEC4E gene had an AUC of 0.786 in predicting STEMI. Additionally, a prognostic model was developed to stratify the risk of heart failure progression, and SI00AI2 was a common biomarker between STEMI and NSTEMI patients.